IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.

Date publication

décembre 2021

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno , Pr WESTEEL Virginie

Tous les auteurs :
Molinier O, Besse B, Barlesi F, Audigier-Valette C, Friard S, Monnet I, Jeannin G, Mazières J, Cadranel J, Hureaux J, Hilgers W, Quoix E, Coudert B, Moro-Sibilot D, Fauchon E, Westeel V, Brun P, Langlais A, Morin F, Souquet PJ, Girard N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34953398

Résumé

Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the standard of care in patients with advanced non-small-cell lung cancer (NSCLC).

Mots clés

chemotherapy, immunotherapy, lung cancer, non-small-cell lung cancer, real-life evidence, sequence

Référence

ESMO Open. 2021 Dec 22;7(1):100353